Novartis

News

Novartis considers "pay-for-performance" for CAR-T

Novartis is considering a “pay-for-performance” pricing scheme if its CAR-T therapy gets approved, following trial results published earlier this week.

News

Teva plans migraine drug filing later this year

Blockbuster hopeful could launch next year if approved.

News

FDA to review Novartis CAR-T next month

If all goes well, FDA could approve CTL109 by late September

News

Novartis and IBM Watson form breast cancer pact

Partnership aims at improving outcomes in advanced breast cancer.

News

Teva on track to file migraine blockbuster

Phase 3 success for fremanezumab.

News

Sandoz files Humira and Remicade biosimilars in EU

European regulators to review Sandoz’s Humira and Remicade biosimilars.

Novartis considers "pay-for-performance" for CAR-T

Teva plans migraine drug filing later this year

FDA to review Novartis CAR-T next month

Novartis and IBM Watson form breast cancer pact

Teva on track to file migraine blockbuster

Sandoz files Humira and Remicade biosimilars in EU

Gilead strikes again, penning $5bn deal to buy Tubulis

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks